{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,17]],"date-time":"2026-05-17T10:36:31Z","timestamp":1779014191021,"version":"3.51.4"},"reference-count":85,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Lancet Regional Health - Europe"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.lanepe.2022.100513","type":"journal-article","created":{"date-parts":[[2022,9,28]],"date-time":"2022-09-28T02:07:37Z","timestamp":1664330857000},"page":"100513","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["BNT162b2 COVID-19 vaccination uptake, safety, effectiveness and waning in children and young people aged 12\u201317 years in Scotland"],"prefix":"10.1016","volume":"23","author":[{"given":"Igor","family":"Rudan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tristan","family":"Millington","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen","family":"Antal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zoe","family":"Grange","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lynda","family":"Fenton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher","family":"Sullivan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Audrey","family":"Buelo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachael","family":"Wood","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lana","family":"Woolford","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olivia V.","family":"Swann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Josephine L.K.","family":"Murray","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucy A.","family":"Cullen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emily","family":"Moore","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fasih","family":"Haider","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7164-2460","authenticated-orcid":false,"given":"Fatima","family":"Almaghrabi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jim","family":"McMenamin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Utkarsh","family":"Agrawal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5672-0443","authenticated-orcid":false,"given":"Syed Ahmar","family":"Shah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven","family":"Kerr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5194-8083","authenticated-orcid":false,"given":"Colin R.","family":"Simpson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Srinivasa Vittal","family":"Katikireddi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sir Lewis D.","family":"Ritchie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chris","family":"Robertson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sir Aziz","family":"Sheikh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.lanepe.2022.100513_bib0001","doi-asserted-by":"crossref","first-page":"01010","DOI":"10.7189\/jogh.11.01010","article-title":"EAVE II Collaboration. The COVID-19 pandemic in children and young people during 2020-2021: learning about clinical presentation, patterns of spread, viral load, diagnosis and treatment","volume":"11","author":"Rudan","year":"2021","journal-title":"J Glob Health"},{"key":"10.1016\/j.lanepe.2022.100513_bib0002","doi-asserted-by":"crossref","first-page":"01011","DOI":"10.7189\/jogh.11.01011","article-title":"EAVE II Collaboration. The COVID-19 pandemic in children and young people during 2020-2021: a complex discussion on vaccination","volume":"11","author":"Rudan","year":"2021","journal-title":"J Glob Health"},{"issue":"6","key":"10.1016\/j.lanepe.2022.100513_bib0003","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1038\/s41591-021-01330-9","article-title":"Safety and immunogenicity of the SARS-CoV-2 BNT162b1 mRNA vaccine in younger and older Chinese adults: a randomized, placebo-controlled, double-blind phase 1 study","volume":"27","author":"Li","year":"2021","journal-title":"Nat Med"},{"issue":"12","key":"10.1016\/j.lanepe.2022.100513_bib0004","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1016\/S1473-3099(21)00319-4","article-title":"Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents: a double-blind, randomised, controlled, phase 1\/2 clinical trial","volume":"21","author":"Han","year":"2021","journal-title":"Lancet Infect Dis"},{"issue":"3","key":"10.1016\/j.lanepe.2022.100513_bib0005","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1056\/NEJMoa2107456","article-title":"C4591001 Clinical Trial Group. Safety, immunogenicity, and efficacy of the BNT162b2 COVID-19 vaccine in adolescents","volume":"385","author":"Frenck","year":"2021","journal-title":"N Engl J Med"},{"issue":"24","key":"10.1016\/j.lanepe.2022.100513_bib0006","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.1056\/NEJMoa2109522","article-title":"Evaluation of mRNA-1273 SARS-CoV-2 vaccine in adolescents","volume":"385","author":"Ali","year":"2021","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.lanepe.2022.100513_bib0007","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/S1473-3099(21)00462-X","article-title":"Safety and immunogenicity of an inactivated COVID-19 vaccine, BBIBP-CorV, in people younger than 18 years: a randomised, double-blind, controlled, phase 1\/2 trial","volume":"22","author":"Xia","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.lanepe.2022.100513_bib0008","first-page":"ciab845","article-title":"Safety and immunogenicity of a recombinant adenovirus type-5-vectored COVID-19 vaccine with a homologous prime-boost regimen in healthy participants aged 6 years and above: a randomised, double-blind, placebo-controlled, phase 2b trial","author":"Zhu","year":"2021","journal-title":"Clin Infect Dis"},{"issue":"1","key":"10.1016\/j.lanepe.2022.100513_bib0009","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1056\/NEJMoa2116298","article-title":"C4591007 Clinical Trial Group. Evaluation of the BNT162b2 COVID-19 vaccine in children 5 to 11 years of age","volume":"386","author":"Walter","year":"2022","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.lanepe.2022.100513_bib0010","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.3390\/vaccines9101102","article-title":"Safety, immunogenicity, and efficacy of COVID-19 vaccines in children and adolescents: a systematic review","volume":"9","author":"Lv","year":"2021","journal-title":"Vaccines"},{"issue":"35","key":"10.1016\/j.lanepe.2022.100513_bib0011","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.15585\/mmwr.mm7035e1","article-title":"COVID-19 vaccination coverage among adolescents aged 12-17 years - United States, December 14, 2020-July 31, 2021","volume":"70","author":"Murthy","year":"2021","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"1","key":"10.1016\/j.lanepe.2022.100513_bib0012","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1111\/apa.16157","article-title":"Vaccinating children and adolescents against severe acute respiratory syndrome corona virus 2 (SARS-CoV-2), updated data from Israel","volume":"111","author":"Glikman","year":"2022","journal-title":"Acta Paediatr"},{"issue":"3","key":"10.1016\/j.lanepe.2022.100513_bib0013","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2021-052478","article-title":"Symptomatic acute myocarditis in 7 adolescents after Pfizer-Biontech COVID-19 vaccination","volume":"148","author":"Marshall","year":"2021","journal-title":"Pediatrics"},{"issue":"29","key":"10.1016\/j.lanepe.2022.100513_bib0014","doi-asserted-by":"crossref","first-page":"3790","DOI":"10.1016\/j.vaccine.2021.05.087","article-title":"Myocarditis following COVID-19 mRNA vaccination","volume":"39","author":"Abu Mouch","year":"2021","journal-title":"Vaccine"},{"key":"10.1016\/j.lanepe.2022.100513_bib0015","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2109730","article-title":"Myocarditis after BNT162b2 mRNA vaccine against COVID-19 in Israel","author":"Mevorach","year":"2021","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.lanepe.2022.100513_bib0016","first-page":"902","article-title":"Adolescent myocarditis after COVID-19 vaccination is rare","volume":"326","author":"Kuehn","year":"2021","journal-title":"JAMA"},{"issue":"31","key":"10.1016\/j.lanepe.2022.100513_bib0017","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.15585\/mmwr.mm7031e1","article-title":"COVID-19 vaccine safety in adolescents aged 12-17 years - United States, December 14, 2020-July 16, 2021","volume":"70","author":"Hause","year":"2021","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"1","key":"10.1016\/j.lanepe.2022.100513_bib0018","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1080\/22221751.2022.2050952","article-title":"Adverse events of special interest following the use of BNT162b2 in adolescents: a population-based retrospective cohort study","volume":"11","author":"Lai","year":"2022","journal-title":"Emerg Microbes Infect"},{"issue":"5","key":"10.1016\/j.lanepe.2022.100513_bib0019","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/j.vaccine.2021.12.044","article-title":"Safety and effectiveness of BNT162b2 mRNA COVID-19 vaccine in adolescents","volume":"40","author":"June Choe","year":"2022","journal-title":"Vaccine"},{"issue":"9","key":"10.1016\/j.lanepe.2022.100513_bib0020","doi-asserted-by":"crossref","first-page":"347","DOI":"10.15585\/mmwr.mm7109e2","article-title":"Safety monitoring of COVID-19 vaccine booster doses among persons aged 12-17 years - United States, December 9, 20 February 2021, 2022","volume":"71","author":"Hause","year":"2022","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"5152","key":"10.1016\/j.lanepe.2022.100513_bib0021","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.15585\/mmwr.mm705152a1","article-title":"COVID-19 vaccine safety in children aged 5-11 years - United States, November 3-December 19, 2021","volume":"70","author":"Hause","year":"2021","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"11","key":"10.1016\/j.lanepe.2022.100513_bib0022","doi-asserted-by":"crossref","first-page":"2919","DOI":"10.3201\/eid2711.211886","article-title":"Effectiveness of BNT162b2 vaccine in adolescents during outbreak of SARS-CoV-2 delta variant infection, Israel, 2021","volume":"27","author":"Glatman-Freedman","year":"2021","journal-title":"Emerg Infect Dis"},{"issue":"42","key":"10.1016\/j.lanepe.2022.100513_bib0023","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.15585\/mmwr.mm7042e1","article-title":"Overcoming COVID-19 Investigators. Effectiveness of Pfizer-Biontech mRNA vaccination against COVID-19 hospitalization among persons aged 12-18 years - United States, June-September 2021","volume":"70","author":"Olson","year":"2021","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"20","key":"10.1016\/j.lanepe.2022.100513_bib0024","first-page":"2002","article-title":"COVID-19 vaccine highly effective against adolescent hospitalizations","volume":"326","author":"Kuehn","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.lanepe.2022.100513_bib0025","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1056\/NEJMc2114290","article-title":"Effectiveness of BNT162b2 vaccine against delta variant in adolescents","volume":"385","author":"Reis","year":"2021","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.lanepe.2022.100513_bib0026","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.0935","article-title":"Yale SARS-CoV-2 Genomic Surveillance Initiative. Assessment of clinical effectiveness of BNT162b2 COVID-19 vaccine in US adolescents","volume":"5","author":"Oliveira","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"5152","key":"10.1016\/j.lanepe.2022.100513_bib0027","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.15585\/mmwr.mm705152a2","article-title":"Interim estimate of vaccine effectiveness of BNT162b2 (Pfizer-BioNTech) vaccine in preventing SARS-CoV-2 infection among adolescents aged 12-17 years - Arizona, July-December 2021","volume":"70","author":"Lutrick","year":"2021","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"2","key":"10.1016\/j.lanepe.2022.100513_bib0028","doi-asserted-by":"crossref","first-page":"52","DOI":"10.15585\/mmwr.mm7102e1","article-title":"Effectiveness of BNT162b2 (Pfizer-BioNTech) mRNA vaccination against multisystem inflammatory syndrome in children among persons aged 12-18 years - United States, July-December 2021","volume":"71","author":"Zambrano","year":"2022","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"8","key":"10.1016\/j.lanepe.2022.100513_bib0029","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1056\/NEJMoa2117995","article-title":"Overcoming Covid-19 Investigators. Effectiveness of BNT162b2 vaccine against critical COVID-19 in adolescents","volume":"386","author":"Olson","year":"2022","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.lanepe.2022.100513_bib0030","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S1473-3099(22)00177-3","article-title":"Effectiveness of BNT162b2 against COVID-19 in adolescents","volume":"22","author":"Powell","year":"2022","journal-title":"Lancet Infect Dis"},{"issue":"11","key":"10.1016\/j.lanepe.2022.100513_bib0031","doi-asserted-by":"crossref","first-page":"422","DOI":"10.15585\/mmwr.mm7111e1","article-title":"Effectiveness of 2-Dose BNT162b2 (Pfizer Biontech) mRNA vaccine in preventing SARS-CoV-2 infection among children aged 5-11 years and adolescents aged 12-15 years - PROTECT Cohort, July 2021-February 2022","volume":"71","author":"Fowlkes","year":"2022","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"9","key":"10.1016\/j.lanepe.2022.100513_bib0032","doi-asserted-by":"crossref","first-page":"352","DOI":"10.15585\/mmwr.mm7109e3","volume":"71","author":"Klein","year":"2022","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"4","key":"10.1016\/j.lanepe.2022.100513_bib0033","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1056\/NEJMoa2115481","article-title":"Duration of protection against mild and severe disease by COVID-19 vaccines","volume":"386","author":"Andrews","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lanepe.2022.100513_bib0034","doi-asserted-by":"crossref","unstructured":"Prunas O, Weinberger DM, Pitzer VE, Gazit S, Patalon T. Waning effectiveness of the BNT162b2 vaccine against infection in adolescents. medRxiv [Preprint]. 2022:2022.01.04.22268776. https:\/\/doi.org\/10.1101\/2022.01.04.22268776","DOI":"10.1101\/2022.01.04.22268776"},{"key":"10.1016\/j.lanepe.2022.100513_bib0035","unstructured":"https:\/\/www.gov.uk\/government\/publications\/COVID-19-vaccination-resources-for-children-and-young-people. Accessed 26 March 2022"},{"key":"10.1016\/j.lanepe.2022.100513_bib0036","unstructured":"https:\/\/www.gov.uk\/government\/groups\/joint-committee-on-vaccination-and-immunisation. Accessed 26 March 2022"},{"key":"10.1016\/j.lanepe.2022.100513_bib0037","unstructured":"https:\/\/www.nhsinform.scot\/COVID-19-vaccine\/the-vaccines\/vaccinating-children-and-young-people-aged-12-to-17-years\/. Accessed 26 March 2022"},{"key":"10.1016\/j.lanepe.2022.100513_bib0038","unstructured":"Vaccine Adverse Event Reporting System (VAERS). Available from: https:\/\/vaers.hhs.gov\/. Accessed 26 March 2022."},{"key":"10.1016\/j.lanepe.2022.100513_bib0039","unstructured":"Centre for Disease Control. v-safe after vaccination health checker. Available from: https:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/vaccines\/safety\/vsafe.html. Accessed 26 March 2022"},{"key":"10.1016\/j.lanepe.2022.100513_bib0040","unstructured":"https:\/\/www.gov.scot\/news\/vaccinations-for-16-to-17-year-olds\/. Accessed 26 March 2022"},{"key":"10.1016\/j.lanepe.2022.100513_bib0041","unstructured":"https:\/\/www.gov.scot\/news\/vaccinations-for-12-15-year-olds\/. Accessed 26 March 2022"},{"key":"10.1016\/j.lanepe.2022.100513_bib0042","unstructured":"https:\/\/www.gov.scot\/news\/vaccinations-for-all-five-to-11-year-olds\/. Accessed 26 March 2022"},{"key":"10.1016\/j.lanepe.2022.100513_bib0043","unstructured":"https:\/\/www.publichealthscotland.scot\/our-areas-of-work\/COVID-19\/covid-19-vaccinations\/covid-19-vaccine-information-and-resources\/eligible-groups\/. Accessed 26 March 2022"},{"key":"10.1016\/j.lanepe.2022.100513_bib0044","doi-asserted-by":"crossref","first-page":"05026","DOI":"10.7189\/jogh.11.05026","article-title":"Uptake, effectiveness and safety of COVID-19 vaccines in children and young people in Scotland: protocol for early pandemic evaluation and enhanced surveillance of COVID-19 (EAVE II)","volume":"11","author":"Adeloye","year":"2021","journal-title":"J Glob Health"},{"issue":"4","key":"10.1016\/j.lanepe.2022.100513_bib0045","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1093\/ije\/dyab028","article-title":"Cohort profile: early pandemic evaluation and enhanced surveillance of COVID-19 (EAVE II) database","volume":"50","author":"Mulholland","year":"2021","journal-title":"Int J Epidemiol"},{"issue":"10293","key":"10.1016\/j.lanepe.2022.100513_bib0046","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1016\/S0140-6736(21)01358-1","article-title":"SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness","volume":"397","author":"Sheikh","year":"2021","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.lanepe.2022.100513_bib0047","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1038\/s41591-021-01630-0","article-title":"Risks of myocarditis, pericarditis, and cardiac arrhythmias associated with COVID-19 vaccination or SARS-CoV-2 infection","volume":"28","author":"Patone","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.lanepe.2022.100513_bib0048","unstructured":"https:\/\/publichealthscotland.scot\/our-areas-of-work\/covid-19\/covid-19-data-and-intelligence\/covid-19-weekly-report-for-scotland\/ Accessed 31 March 2022"},{"key":"10.1016\/j.lanepe.2022.100513_bib0049","unstructured":"https:\/\/www.who.int\/vaccine_safety\/committee\/Module_AESI.pdf Accessed 26 March 2022"},{"key":"10.1016\/j.lanepe.2022.100513_bib0050","unstructured":"Safety Platform for Emergency vACcines (SPEAC) - Brighton Collaboration.Available from: https:\/\/brightoncollaboration.us\/speac\/. Accessed 26 March 2022."},{"key":"10.1016\/j.lanepe.2022.100513_bib0051","series-title":"Seasonal Influenza Vaccine Effectiveness (SIVE)","author":"Simpson","year":"2013"},{"key":"10.1016\/j.lanepe.2022.100513_bib0052","unstructured":"International Classification of Diseases (ICD-10). Version: 2010. Available from: https:\/\/icd.who.int\/browse10\/2010\/en. Accessed 26 March 2022"},{"key":"10.1016\/j.lanepe.2022.100513_bib0053","unstructured":"National Data Catalogue: National Datasets. Information services division (ISD) Scotland. Available from: https:\/\/www.ndc.scot.nhs.uk\/National-Datasets\/data.asp?SubID=5.Accessed 26 March 2022."},{"issue":"10319","key":"10.1016\/j.lanepe.2022.100513_bib0054","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0140-6736(21)02754-9","article-title":"Two-dose Chadox1 nCoV-19 vaccine protection against COVID-19 hospital admissions and deaths over time: a retrospective, population-based cohort study in Scotland and Brazil","volume":"399","author":"Katikireddi","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.lanepe.2022.100513_bib0055","article-title":"Why isn't the UK vaccinating young children for COVID?","author":"McCall","year":"2021","journal-title":"Medscape"},{"key":"10.1016\/j.lanepe.2022.100513_bib0056","doi-asserted-by":"crossref","DOI":"10.1097\/MCP.0000000000000868","article-title":"COVID 19: vaccines, efficacy and effects on variants","author":"Rudan","year":"2022","journal-title":"Curr Opin Pulm Med"},{"key":"10.1016\/j.lanepe.2022.100513_bib0057","unstructured":"https:\/\/www.imperial.ac.uk\/medicine\/research-and-impact\/groups\/react-study\/real-time-assessment-of-community-transmission-findings\/. Accessed 26 March 2022."},{"key":"10.1016\/j.lanepe.2022.100513_bib0058","unstructured":"https:\/\/www.gov.uk\/government\/publications\/regulatory-approval-of-pfizer-biontech-vaccine-for-covid-19\/summary-of-product-characteristics-for-covid-19-vaccine-pfizerbiontech. Accessed 26 March 2022."},{"key":"10.1016\/j.lanepe.2022.100513_bib0059","unstructured":"https:\/\/www.ons.gov.uk\/peoplepopulationandcommunity\/healthandsocialcare\/causesofdeath\/articles\/covid19vaccinationandmortalityinyoungpeopleduringthecoronaviruspandemic\/2022-03-22. Accessed 26 March 2022."},{"key":"10.1016\/j.lanepe.2022.100513_bib0060","unstructured":"https:\/\/www.isdscotland.org\/health-topics\/hospital-care\/inpatient-and-day-case-activity\/. Accessed 26 March 2022"},{"issue":"10342","key":"10.1016\/j.lanepe.2022.100513_bib0061","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1016\/S0140-6736(22)00791-7","article-title":"Risk of myocarditis and pericarditis after the COVID-19 mRNA vaccination in the USA: a cohort study in claims databases","volume":"399","author":"Wong","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.lanepe.2022.100513_bib0062","unstructured":"https:\/\/www.gosh.nhs.uk\/conditions-and-treatments\/conditions-we-treat\/paediatric-inflammatory-multisystem-syndrome-pims\/"},{"key":"10.1016\/j.lanepe.2022.100513_bib0063","unstructured":"Weaver J. Using negative control outcomes to identify biased study design: a self-controlled case series example. Available from: https:\/\/www.ohdsi.org\/wp-content\/uploads\/2015\/04\/FluAmiSccs.pdf; Accessed 27 July 2022."},{"issue":"12","key":"10.1016\/j.lanepe.2022.100513_bib0064","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1038\/s41591-021-01556-7","article-title":"Neurological complications after first dose of COVID-19 vaccines and SARS-CoV-2 infection","volume":"27","author":"Patone","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.lanepe.2022.100513_bib0065","doi-asserted-by":"crossref","first-page":"n1931","DOI":"10.1136\/bmj.n1931","article-title":"Risk of thrombocytopenia and thromboembolism after COVID-19 vaccination and SARS-CoV-2 positive testing: self-controlled case series study","volume":"374","author":"Hippisley-Cox","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.lanepe.2022.100513_bib0066","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1097\/EDE.0b013e3181d61eeb","article-title":"Negative controls: a tool for detecting confounding and bias in observational studies","volume":"21","author":"Lipsitch","year":"2010","journal-title":"Epidemiology"},{"key":"10.1016\/j.lanepe.2022.100513_bib0067","unstructured":"https:\/\/www.theguardian.com\/world\/2021\/dec\/22\/lateral-flow-tests-covid-Omicron-explainer"},{"issue":"1","key":"10.1016\/j.lanepe.2022.100513_bib0068","doi-asserted-by":"crossref","first-page":"e545","DOI":"10.1093\/cid\/ciac262","article-title":"SARS-CoV-2 naturally acquired immunity vs. vaccine-induced immunity, reinfections versus breakthrough infections: a retrospective cohort study","volume":"75","author":"Gazit","year":"2022","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.lanepe.2022.100513_bib0069","article-title":"Paediatric multisystem inflammatory syndrome temporally associated with SARS-CoV-2 (PIMS-TS): prospective, national surveillance, United Kingdom and Ireland, 2020","volume":"3","author":"Flood","year":"2021","journal-title":"Lancet Reg Health Eur"},{"key":"10.1016\/j.lanepe.2022.100513_bib0070","unstructured":"Public Health Scotland. COVID-19 & winter statistical report. Available from: https:\/\/publichealthscotland.scot\/media\/12575\/22-04-06-covid19-winter_publication_report.pdf. Accessed 31 March 2022"},{"key":"10.1016\/j.lanepe.2022.100513_bib0071","doi-asserted-by":"crossref","unstructured":"Florentino PTV, Millington T, Cerqueira-Silva T et al. Vaccine effectiveness of two-dose BNT162b2 over time against COVID-19 symptomatic infection and severe cases among adolescents: test negative design case-control studies in Brazil and Scotland (preprint). Available at SSRN: https:\/\/ssrn.com\/abstract=4074678 or https:\/\/doi.org\/10.2139\/ssrn.4074678","DOI":"10.2139\/ssrn.4074678"},{"issue":"8","key":"10.1016\/j.lanepe.2022.100513_bib0072","doi-asserted-by":"crossref","DOI":"10.2196\/37821","article-title":"Methodological issues for using a common data model (CDM) of COVID-19 vaccine uptake and important adverse events of interest (AEIs): the data and connectivity COVID-19 vaccines pharmacovigilance (DaC-VaP) United Kingdom feasibility study","volume":"6","author":"Delanerolle","year":"2022","journal-title":"JMIR Form Res"},{"issue":"7","key":"10.1016\/j.lanepe.2022.100513_bib0073","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1038\/s41591-021-01408-4","article-title":"First-dose Chadox1 and BNT162b2 COVID-19 vaccines and thrombocytopenic, thromboembolic and hemorrhagic events in Scotland","volume":"27","author":"Simpson","year":"2021","journal-title":"Nat Med"},{"issue":"2","key":"10.1016\/j.lanepe.2022.100513_bib0074","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1003927","article-title":"First dose Chadox1 and BNT162b2 COVID-19 vaccinations and cerebral venous sinus thrombosis: a pooled self-controlled case series study of 11.6 million individuals in England, Scotland, and Wales","volume":"19","author":"Kerr","year":"2022","journal-title":"PLoS Med"},{"issue":"10285","key":"10.1016\/j.lanepe.2022.100513_bib0075","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1016\/S0140-6736(21)00677-2","article-title":"Interim findings from first-dose mass COVID-19 vaccination roll-out and COVID-19 hospital admissions in Scotland: a national prospective cohort study","volume":"397","author":"Vasileiou","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.lanepe.2022.100513_bib0076","doi-asserted-by":"crossref","first-page":"05025","DOI":"10.7189\/jogh.12.05025","article-title":"COVID-19 vaccine effectiveness against symptomatic SARS-CoV-2 infection and severe COVID-19 outcomes from Delta AY.4.2: Cohort and test-negative study of 5.4 million individuals in Scotland","volume":"12","author":"Kerr","year":"2022","journal-title":"J Glob Health"},{"issue":"7","key":"10.1016\/j.lanepe.2022.100513_bib0077","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/S1473-3099(22)00141-4","article-title":"Severity of omicron variant of concern and effectiveness of vaccine boosters against symptomatic disease in Scotland (EAVE II): a national cohort study with nested test-negative design","volume":"22","author":"Sheikh","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.lanepe.2022.100513_bib0078","doi-asserted-by":"crossref","DOI":"10.3389\/fpubh.2022.829176","article-title":"Safety, immunogenicity, and efficacy of COVID-19 vaccines in adolescents, children, and infants: a systematic review and meta-analysis","volume":"10","author":"Du","year":"2022","journal-title":"Front Public Health"},{"issue":"22","key":"10.1016\/j.lanepe.2022.100513_bib0079","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1001\/jama.2022.7493","article-title":"Association of prior BNT162b2 COVID-19 vaccination with symptomatic SARS-CoV-2 infection in children and adolescents during omicron predominance","volume":"327","author":"Fleming-Dutra","year":"2022","journal-title":"JAMA"},{"issue":"12","key":"10.1016\/j.lanepe.2022.100513_bib0080","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1136\/archdischild-2021-321604","article-title":"Sharing a household with children and risk of COVID-19: a study of over 300,000 adults living in healthcare worker households in Scotland","volume":"106","author":"Wood","year":"2021","journal-title":"Arch Dis Child"},{"key":"10.1016\/j.lanepe.2022.100513_bib0081","doi-asserted-by":"crossref","first-page":"n2060","DOI":"10.1136\/bmj.n2060","article-title":"Risk of hospital admission with COVID-19 among teachers compared with healthcare workers and other adults of working age in Scotland, March 2020 to July 2021: population based case-control study","volume":"374","author":"Fenton","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.lanepe.2022.100513_bib0082","doi-asserted-by":"crossref","DOI":"10.3389\/fpubh.2021.767447","article-title":"Effect of a concise educational program on COVID-19 vaccination attitudes","volume":"9","author":"Kaim","year":"2021","journal-title":"Front Public Health"},{"key":"10.1016\/j.lanepe.2022.100513_bib0083","doi-asserted-by":"crossref","DOI":"10.1016\/j.hlpt.2021.100584","article-title":"Finding the way forward: COVID-19 vaccination progress in Germany, Austria and Switzerland","volume":"11","author":"Desson","year":"2022","journal-title":"Health Policy Technol"},{"key":"10.1016\/j.lanepe.2022.100513_bib0084","doi-asserted-by":"crossref","first-page":"7140","DOI":"10.1016\/j.vaccine.2021.10.077","article-title":"Social inequalities in COVID-19 vaccine acceptance and uptake for children and adolescents in Montreal, Canada","volume":"39","author":"McKinnon","year":"2021","journal-title":"Vaccine"},{"key":"10.1016\/j.lanepe.2022.100513_bib0085","doi-asserted-by":"crossref","first-page":"997","DOI":"10.15585\/mmwr.mm7028e1","article-title":"Acceptability of adolescent COVID-19 vaccination among adolescents and parents of adolescents - United States, April 15-23, 2021","volume":"70","author":"Scherer","year":"2021","journal-title":"MMWR Morb Mortal Wkly Rep"}],"container-title":["The Lancet Regional Health - Europe"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666776222002095?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666776222002095?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T04:56:10Z","timestamp":1763009770000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666776222002095"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":85,"alternative-id":["S2666776222002095"],"URL":"https:\/\/doi.org\/10.1016\/j.lanepe.2022.100513","relation":{},"ISSN":["2666-7762"],"issn-type":[{"value":"2666-7762","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"BNT162b2 COVID-19 vaccination uptake, safety, effectiveness and waning in children and young people aged 12\u201317 years in Scotland","name":"articletitle","label":"Article Title"},{"value":"The Lancet Regional Health - Europe","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lanepe.2022.100513","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100513"}}